Crestor's EU indication broadened for "high risk" patients
This article was originally published in Scrip
Executive Summary
The EU has approved AstraZeneca's blockbuster Crestor (rosuvastatin) for patients with a high risk of experiencing a first cardiovascular event. The expansion follows a similar move by the US earlier in the year (scripnews.com, 9 February 2010).